Strategic commercial advisor with nearly two decades in pharma and biotech across North America and Europe.
I'm a strategic commercial advisor with nearly two decades in pharma and biotech across North America and Europe, holding a PhD in infection biology and an MBA from UBC's Sauder School of Business.
Most recently at AbCellera, I led early commercial planning and value assessment for preclinical assets and presented recommendations for pipeline investment decisions and commercial program strategy to the Board of Directors. This work built on more than 15 years working for Merck/MSD, supporting drug launches and lifecycle management in medical affairs, market access, and pricing roles for blockbuster products including KEYTRUDA (oncology), SIMPONI (rheumatology), and ZEPATIER (virology).
I'm passionate about bringing this experience and a numbers-and-logic-driven mind to your company's pipeline and asset planning, helping you make high-stakes decisions with conviction.
Heidi brought deep scientific and commercial rigor, along with an indispensable understanding of what drives a successful drug launch, from key opinion leader buy-in to payer and market-access realities. Working across our preclinical assets, she built the early commercial strategy and valuations for multiple programs and significantly reshaped their positioning, strengthening the commercial case for each, with direct implications for preclinical and clinical development plans. Her recommendations directly informed Go/No-Go decisions at the executive level, and her analyses shaped the corporate strategy for program selection. She has an exceptional ability to see the long-term picture, shift programs away from potential commercial pitfalls, and present recommendations so a leadership team and board can act with confidence. I'd recommend her to any early-stage biotech that wants to make sharper pipeline and investment decisions.